Interesting, the two patients (one in each dose level group) with disease progression in our ongoing P1 CHM1101 trial also happen to be the ones that received the least number of doses, while the other five patients with more than 3 doses received achieved disease control for glioblastoma:
- Forums
- ASX - By Stock
- Chimeric: Media Thread
Interesting, the two patients (one in each dose level group)...
-
-
- There are more pages in this discussion • 328 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CHM (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.52M |
Open | High | Low | Value | Volume |
2.2¢ | 2.2¢ | 2.0¢ | $7.495K | 357.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 2.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.2¢ | 729299 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 0.021 |
5 | 374162 | 0.020 |
6 | 1232233 | 0.019 |
6 | 450000 | 0.018 |
4 | 1007660 | 0.017 |
Price($) | Vol. | No. |
---|---|---|
0.022 | 729299 | 3 |
0.023 | 150000 | 1 |
0.024 | 400000 | 3 |
0.026 | 255000 | 3 |
0.027 | 45000 | 1 |
Last trade - 10.22am 24/07/2024 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
Previous Video
Next Video
SPONSORED BY The Market Online